Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00328211 · ClinicalTrials.gov registry record · NA
Intralumenal Effects on Cholesterol Absorption/Synthesis
A NA study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT00328211: Completed NA study, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT00328211 is a NA study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00328211, a NA study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
The overall goal of this study is to better understand how cholesterol is absorbed and utilized in the body(metabolism) and how serum cholesterol affects the development of hardening of the arteries (atherosclerosis). The purpose of aim 1 is to assess the role of the amount of different bile acids in the intestine and how they affect the absorption, synthesis and digestion of cholesterol. The effect that these bile acids have on how fast the gall bladder empties and the release of a hormone in the blood after a meal will also be studied. The purpose of aim 2 is to assess the role of phospholipid (a fat containing the element phosphorus) in the intestine and how it affects the absorption, synthesis and digestion of cholesterol in normal people and in people with a genetic condition (mdr3 deficiency)that affects phospholipid and bile acid metabolism. The purpose of aim 3 is to assess the role of a material that acts like a detergent called Pluronic F-68 which is known to block the absorption of cholesterol. The purpose of aim 4 is to determine if the cholesterol from food and the cholesterol made by the body are digested and absorbed differently.
Interventions
- DIETARY_SUPPLEMENT Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)
- DIETARY_SUPPLEMENT Sphingomyelin
- OTHER C13 Stable isotope of Cholesterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2005-09 |
| Est. Completion | 2013-12 |
| Phase | NA |
What the finished NCT00328211 record still lists
NCT00328211 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic) is the first listed.
NCT00328211 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00328211 about?
NCT00328211 is a clinical study titled "Intralumenal Effects on Cholesterol Absorption/Synthesis". The overall goal of this study is to better understand how cholesterol is absorbed and utilized in the body(metabolism) and how serum cholesterol affects the development of hardening of the arteries (atherosclerosis). The purpose of aim 1 is to assess the role of the amount of different bile acids i...
What is the current status of trial NCT00328211?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2005-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00328211?
The interventions under investigation include: Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic) (DIETARY_SUPPLEMENT), Sphingomyelin (DIETARY_SUPPLEMENT), C13 Stable isotope of Cholesterol (OTHER).
Who is sponsoring clinical trial NCT00328211?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00328211's enrollment target sits among peer trials
35 1564th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia